Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients.
de Menthon, Mathilde
Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. [electronic resource] - Clinical and experimental rheumatology - S63-71 p. digital
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
0392-856X
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Murine-Derived--adverse effects
Chi-Square Distribution
Drug Resistance
Drug Substitution
Female
France
Granulomatosis with Polyangiitis--diagnosis
Humans
Immunosuppressive Agents--adverse effects
Infliximab
Kaplan-Meier Estimate
Male
Middle Aged
Patient Selection
Prospective Studies
Recurrence
Remission Induction
Risk Assessment
Risk Factors
Rituximab
Severity of Illness Index
Time Factors
Treatment Outcome
Young Adult
Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. [electronic resource] - Clinical and experimental rheumatology - S63-71 p. digital
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
0392-856X
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Murine-Derived--adverse effects
Chi-Square Distribution
Drug Resistance
Drug Substitution
Female
France
Granulomatosis with Polyangiitis--diagnosis
Humans
Immunosuppressive Agents--adverse effects
Infliximab
Kaplan-Meier Estimate
Male
Middle Aged
Patient Selection
Prospective Studies
Recurrence
Remission Induction
Risk Assessment
Risk Factors
Rituximab
Severity of Illness Index
Time Factors
Treatment Outcome
Young Adult